<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016805</url>
  </required_header>
  <id_info>
    <org_study_id>UTX-TGR-208</org_study_id>
    <nct_id>NCT04016805</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax</brief_title>
  <official_title>A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TG Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TG Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate&#xD;
      of minimal residual disease (MRD) negativity in subjects with Chronic Lymphocytic Leukemia&#xD;
      (CLL), who are currently on treatment with ibrutinib, alacabrutinib or venetoclax.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 open label, two treatment cohort trial evaluating the addition of&#xD;
      ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in&#xD;
      subjects with CLL, who fail to achieve MRD negativity, after a minimum 6-month treatment with&#xD;
      ibrutinib, alacabrutinib or venetoclax.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of minimal residual disease negativity</measure>
    <time_frame>24 months</time_frame>
    <description>Assess the rate of undetectable minimal residual disease (U-MRD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Objective response in subjects treated on study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events that are Related to Treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>ublituximab + umbralisib + ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter&#xD;
umbralisib: 800 mg; to be administered daily&#xD;
ibrutinib: dose tolerated by subject; to be administered daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ublituximab + umbralisib + venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter&#xD;
umbralisib: 800 mg; to be administered daily&#xD;
venetoclax: dose tolerated by subject; to be administered daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ublituximab + umbralisib + acalabrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter&#xD;
umbralisib: 800 mg; to be administered daily&#xD;
acalabrutinib: previously tolerated dose; to be administered every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ublituximab</intervention_name>
    <description>recombinant chimeric anti-CD20 monoclonal antibody&#xD;
administered as an IV infusion</description>
    <arm_group_label>ublituximab + umbralisib + acalabrutinib</arm_group_label>
    <arm_group_label>ublituximab + umbralisib + ibrutinib</arm_group_label>
    <arm_group_label>ublituximab + umbralisib + venetoclax</arm_group_label>
    <other_name>TG-1101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Umbralisib</intervention_name>
    <description>Phosphoinositide-3-kinase (PI3K) delta inhibitor&#xD;
Tablet form, to taken orally on a daily basis</description>
    <arm_group_label>ublituximab + umbralisib + acalabrutinib</arm_group_label>
    <arm_group_label>ublituximab + umbralisib + ibrutinib</arm_group_label>
    <arm_group_label>ublituximab + umbralisib + venetoclax</arm_group_label>
    <other_name>TGR-1202</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Bruton Tyrosine Kinase (BTK) inhibitor&#xD;
Tablet form, to taken orally on a daily basis</description>
    <arm_group_label>ublituximab + umbralisib + ibrutinib</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>BCL-2 inhibitor&#xD;
Tablet form, to be taken orally</description>
    <arm_group_label>ublituximab + umbralisib + venetoclax</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib Oral Capsule</intervention_name>
    <description>Kinase inhibitor, capsule form, to be taken orally</description>
    <arm_group_label>ublituximab + umbralisib + acalabrutinib</arm_group_label>
    <other_name>Calquence</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with Chronic Lymphocytic Leukemia (CLL) who have been on treatment for at&#xD;
             least 6 months&#xD;
&#xD;
          -  Minimal Residual Disease positive at screening&#xD;
&#xD;
          -  Adequate organ system function as specified in the protocol&#xD;
&#xD;
          -  Ability to follow protocol procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects receiving cancer therapy or any investigational drug within 21 days of Cycle&#xD;
             1, Day 1.&#xD;
&#xD;
          -  Subjects with a known histological transformation&#xD;
&#xD;
          -  Active Hepatitis B or Hepatitis C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TG Therapeutics Clinical Support Team</last_name>
    <phone>1-877-555-8489</phone>
    <email>clinicalsupport@tgtxinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>umbralisib</keyword>
  <keyword>ublituximab</keyword>
  <keyword>venetoclax</keyword>
  <keyword>ibrutinib</keyword>
  <keyword>CLL</keyword>
  <keyword>acalabrutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Acalabrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

